News09/06/2026
Formation Bio begins first-in-human BLKR201 trial
Formation Bio, Inc. →Formation Bio announced the first participant dosed in a Phase 1 study of BLKR201, an investigational CNS-penetrant TYK2 inhibitor. The healthy-volunteer study includes single- and multiple-ascending-dose components. The asset was licensed from Lynk Pharmaceuticals and is developed through subsidiary Bleecker Bio. The company said it progressed from deal close to dosing in five months and expected an early-2027 readout. These were company-reported development milestones and expectations; the compound was not FDA approved, and no clinical efficacy conclusion was established.